A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...
First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on ...
Analysis of genomic and immune microenvironment differences in Chinese populations: Revealing potential mechanisms of poor immunotherapy outcomes in patients with EGFR mutation and ALK fusion ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results